Oppenheimer Reiterates a 'Perform' on Myriad Genetics (MYGN); CMS Selects Gapfilling for Molecular Tests, However, Risks Remain
Tweet Send to a Friend
Oppenheimer reiterates a 'Perform' on Myriad Genetics (NASDAQ: MYGN) price target of $29.00.
Analyst, David Ferreiro, said, "CMS announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, David Ferreiro, said, "CMS announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
